SK bioscience, a pharmaceutical affiliate under Korea s SK Group, on Monday unveiled its latest strategic initiative, aimed at preparing for possible pandemics in the future and expanding into emerging sectors in the post-COVID-19 era.
SK bioscience, a pharmaceutical affiliate under South Korea's SK Group, said Friday its typhoid conjugate vaccine has obtained prequalification certification from the World Health Organization. The vaccine, named SKYTyphoid, was jointly developed by the South Korean company and the International Vaccine Institute, with financial support from the Bill & Melinda Gates Foundation, according to SK bioscience. SK.
SK bioscience obtained prequalification (PQ) certification from the World Health Organization (WHO) for a typhoid conjugate vaccine called SKY Typhoid, according to the global vaccine and biotech company, Friday.
SK bioscience began its domestic supply of Novavax’s updated COVID-19 vaccine, which targets the XBB.1.5 variant, Dec. 18, as part of the country’s effort to provide a wider range of vaccine choices in addition to mRNA-based vaccines, according to the vaccine maker, Sunday.
SK Bioscience announced Wednesday that the company would supply Novavax's updated COVID-19 vaccine in South Korea, as part of the government’s winter vaccine program running early next year. SK Bioscience's announcement was made after the Ministry of Food and Drug Safety of South Korea gave emergency use authorization for the Novavax COVID-19 vaccine earlier in the day. The Korean government’s a.